Trials / Terminated
TerminatedNCT01144351
A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Elan Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of ELND002 in patients with relapsing forms of secondary progressive multiple sclerosis (SPMS) or relapsing-remitting multiple sclerosis (RRMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ELND002 | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2012-12-01
- First posted
- 2010-06-15
- Last updated
- 2015-12-14
Locations
20 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01144351. Inclusion in this directory is not an endorsement.